These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 11773161)
1. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. Agarwala SS; Glaspy J; O'Day SJ; Mitchell M; Gutheil J; Whitman E; Gonzalez R; Hersh E; Feun L; Belt R; Meyskens F; Hellstrand K; Wood D; Kirkwood JM; Gehlsen KR; Naredi P J Clin Oncol; 2002 Jan; 20(1):125-33. PubMed ID: 11773161 [TBL] [Abstract][Full Text] [Related]
2. The health-related quality-of-life impact of histamine dihydrochloride plus interleukin-2 compared with interleukin-2 alone in patients with metastatic melanoma. Beusterien KM; Ackerman SJ; Plante K; Glaspy J; Naredi P; Wood D; Gehlsen K; Agarwala SS Support Care Cancer; 2003 May; 11(5):304-12. PubMed ID: 12720074 [TBL] [Abstract][Full Text] [Related]
3. Are all hypotheses generated before data analysis prospective? Urba WJ; Alvord WG J Clin Oncol; 2002 Mar; 20(6):1431-3. PubMed ID: 11896085 [No Abstract] [Full Text] [Related]
4. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. Keilholz U; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; Thomas J; Proebstle TM; Schmittel A; Schadendorf D; Velu T; Negrier S; Kleeberg U; Lehman F; Suciu S; Eggermont AM J Clin Oncol; 2005 Sep; 23(27):6747-55. PubMed ID: 16170182 [TBL] [Abstract][Full Text] [Related]
5. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11. Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820 [TBL] [Abstract][Full Text] [Related]
6. Combined treatment with histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma. Lindnér P; Rizell M; Mattsson J; Hellstrand K; Naredi P Anticancer Res; 2004; 24(3b):1837-42. PubMed ID: 15274364 [TBL] [Abstract][Full Text] [Related]
7. A phase II study of outpatient subcutaneous histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma. Schmidt H; Larsen S; Bastholt L; Fode K; Rytter C; Von Der Maase H Ann Oncol; 2002 Dec; 13(12):1919-24. PubMed ID: 12453861 [TBL] [Abstract][Full Text] [Related]
8. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250 [TBL] [Abstract][Full Text] [Related]
9. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514 [TBL] [Abstract][Full Text] [Related]
10. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. Ridolfi R; Chiarion-Sileni V; Guida M; Romanini A; Labianca R; Freschi A; Lo Re G; Nortilli R; Brugnara S; Vitali P; Nanni O; J Clin Oncol; 2002 Mar; 20(6):1600-7. PubMed ID: 11896110 [TBL] [Abstract][Full Text] [Related]
11. Treatment with histamine dihydrochloride and interleukin-2 in patients with advanced metastatic malignant melanoma: a detailed safety analysis. O'Day SJ; Agarwala SS; Naredi P; Kass CL; Gehlsen KR; Glaspy J Melanoma Res; 2003 Jun; 13(3):307-11. PubMed ID: 12777988 [TBL] [Abstract][Full Text] [Related]
12. Subcutaneous interleukin-2 and interferon-alpha therapy associated with cisplatin monochemotherapy in the treatment of metastatic melanoma. Andrès P; Cupissol D; Guillot B; Avril MF; Drèno B Eur J Dermatol; 1998 Jun; 8(4):235-9. PubMed ID: 9649695 [TBL] [Abstract][Full Text] [Related]
13. Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma. Middleton M; Hauschild A; Thomson D; Anderson R; Burdette-Radoux S; Gehlsen K; Hellstrand K; Naredi P Ann Oncol; 2007 Oct; 18(10):1691-7. PubMed ID: 17709802 [TBL] [Abstract][Full Text] [Related]
14. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950 [TBL] [Abstract][Full Text] [Related]
15. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. Gollob JA; Veenstra KG; Parker RA; Mier JW; McDermott DF; Clancy D; Tutin L; Koon H; Atkins MB J Clin Oncol; 2003 Jul; 21(13):2564-73. PubMed ID: 12829677 [TBL] [Abstract][Full Text] [Related]
16. Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104). Asemissen AM; Scheibenbogen C; Letsch A; Hellstrand K; Thorén F; Gehlsen K; Schmittel A; Thiel E; Keilholz U Clin Cancer Res; 2005 Jan; 11(1):290-7. PubMed ID: 15671558 [TBL] [Abstract][Full Text] [Related]
17. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials. Flaherty LE; Atkins M; Sosman J; Weiss G; Clark JI; Margolin K; Dutcher J; Gordon MS; Lotze M; Mier J; Sorokin P; Fisher RI; Appel C; Du W J Clin Oncol; 2001 Jul; 19(13):3194-202. PubMed ID: 11432886 [TBL] [Abstract][Full Text] [Related]
18. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. Chapman PB; Einhorn LH; Meyers ML; Saxman S; Destro AN; Panageas KS; Begg CB; Agarwala SS; Schuchter LM; Ernstoff MS; Houghton AN; Kirkwood JM J Clin Oncol; 1999 Sep; 17(9):2745-51. PubMed ID: 10561349 [TBL] [Abstract][Full Text] [Related]
19. Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma. Masucci GV; Månsson-Brahme E; Ragnarsson-Olding B; Nilsson B; Wagenius G; Hansson J Melanoma Res; 2006 Aug; 16(4):357-63. PubMed ID: 16845332 [TBL] [Abstract][Full Text] [Related]
20. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Lissoni P; Barni S; Tancini G; Ardizzoia A; Ricci G; Aldeghi R; Brivio F; Tisi E; Rovelli F; Rescaldani R Br J Cancer; 1994 Jan; 69(1):196-9. PubMed ID: 8286206 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]